A Randomized Phase I/II Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma
Phase of Trial: Phase I/II
Latest Information Update: 21 Jun 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Ipilimumab
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms NIVIPIT
- 13 Jun 2018 Planned End Date changed from 1 Sep 2020 to 1 Jul 2021.
- 13 Jun 2018 Planned primary completion date changed from 1 Sep 2020 to 1 Jun 2019.
- 08 Aug 2016 New trial record